Much of this may relate to the populations studied — including (a) the stage of progression; (b) the degree of adiposity and insulin resistance; (c) whether or not the participant was weight neutral; (d) the genotype (e.g., PNPLA3); and (e) whether the participant was fed, fasting, or undergoing a clamp study — and to the specific methodology employed. The gene discussed is PNPLA3; the disease is Insulin resistance.